Iovance Biotherapeutics, Inc.
IOVA
$3.78
-$0.10-2.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -9.93% | 21.20% | 18.27% | 3.88% | -47.87% |
| Total Depreciation and Amortization | -17.63% | 8.28% | -2.19% | 9.17% | -36.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.51% | 48.70% | -59.25% | 21.31% | -39.70% |
| Change in Net Operating Assets | -76.66% | 14.53% | -192.85% | 152.53% | 59.74% |
| Cash from Operations | -37.11% | 33.21% | -16.69% | 34.96% | -41.47% |
| Capital Expenditure | 29.10% | 14.05% | -45.34% | -20.13% | -49.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 78.33% | -63.76% | 30.76% | -3.51% | -20.71% |
| Cash from Investing | 1,370.19% | -95.44% | 22.90% | -12.76% | -32.99% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 74.00% | -36.04% | 544.55% | -90.78% | 4,571.03% |
| Repurchase of Common Stock | -839.10% | 4.51% | 7.54% | 91.07% | -541.36% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 67.94% | -36.21% | 565.58% | -90.77% | 6,106.80% |
| Foreign Exchange rate Adjustments | -136.92% | 184.85% | -192.02% | 45.47% | 143.12% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 574.37% | -80.69% | 164.80% | -170.78% | 215.48% |